Groundbreaking results from a recent clinical trial, published by Breakthrough T1D, reveal that all 12 participants have successfully discontinued external insulin use thanks to tegoprubart. This innovative approach involves islet transplants, with tegoprubart playing a critical role in preventing autoimmunity and promoting islet longevity. The trial’s success marks a significant milestone in diabetes management, highlighting the potential of tegoprubart to transform the lives of individuals with Type 1 diabetes by reducing reliance on external insulin. Researchers are optimistic that this could pave the way for more sustainable, long-term solutions for diabetes patients worldwide. As this promising study captures attention, further research is anticipated to explore the widespread application of this treatment. The medical community and patients alike are eagerly awaiting the next steps in this revolutionary approach to diabetes care.
Breakthrough T1DNew data shows Robinhood Chain TVL Surges in First Week
July 11, 2026
The first week of data following the launch of the Robinhood Chain reveals promising insights into its total value locked (TVL). As reported by 99Bitcoins,